jRCT2031260248招募中不适用
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DWJ155 and safety and imaging properties of [68Ga]Ga-DWJ155 in patients with solid tumors (CFML539A12101)
未提供0 个研究点目标入组 7 人开始时间: 待定
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Male or female patients age >= 18 years.
- •Patients with one of the following histologically or cytologically confirmed and documented malignancies who have progressed on or been intolerant to standard of care therapy, and are not considered appropriate for any standard therapy with proven benefit, in the investigator judgment:
- •[Dose Escalation]
- •Advanced HER2+ breast cancer with disease progression after at least two prior lines of systemic therapy in the advanced setting.
- •Advanced HR+/HER2-low breast cancer with disease progression after prior therapy in the advanced setting.
- •Advanced NSCLC without AGAs with disease progression after prior therapy in the advanced setting.
- •Advanced NSCLC with AGAs who have received prior treatment.
- •Measurable disease as determined by RECIST version 1.
- •[Dose Expansion]
- •Advanced HER2+ breast cancer with disease progression after at least two prior lines of systemic therapy in the advanced setting.
- •Advanced HR+/HER2-low breast cancer with disease progression after prior therapy in the advanced setting.
- •Advanced HR+/HER2 0 breast cancer with disease progression after prior therapy in the advanced setting.
- •Advanced HR-/HER2-low breast cancer with disease progression after prior therapy in the advanced setting.
- •Advanced HR-/HER2 0 breast cancer with disease progression after prior therapy in the advanced setting.
- •Advanced NSCLC with AGAs, who have received prior treatment.
- •Advanced NSCLC without known AGAs who have received prior treatment.
- •Advanced gastric/GEJ cancer with HER2 IHC 3+ or 2+ (ISH + or -), following disease progression after prior therapy in the advanced setting.
- •Measurable disease as determined by RECIST version 1.1.
排除标准
- •Out-of-range laboratory values defined as:
- •Creatinine clearance < 60 mL/min (calculated using CKD-EPI 2021 formula, or measured)
- •Total bilirubin > 1.5 x ULN (except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 x ULN) or direct bilirubin > 1.5 x ULN
- •Alanine aminotransferase (ALT) > 3 x ULN, except for patients with tumor involvement of the liver who are excluded if ALT > 5 x ULN
- •Aspartate aminotransferase (AST) > 3 x ULN, except for patients with tumor involvement of the liver who are excluded if AST > 5 x ULN
- •Lipase > 1.5 x ULN
- •Absolute neutrophil count (ANC) < 1.5 x 109/L
- •Hemoglobin < 9 g/dL
- •Platelet count < 100 x 109/L
- •Initiation of hematopoietic colony stimulating factors, thrombopoietin mimetics, or erythroid stimulating agents initiated =< 2 weeks prior to imaging agent administration.
- •Use of transfusion support =<4 weeks prior to imaging agent administration.
- •Impaired cardiac function or clinically significant cardiac disease.
- •Unmanageable urinary tract obstruction or urinary incontinence.
- •Any serious uncontrolled infection (acute or chronic).
- •Pregnant or breastfeeding women.
- •Treatment with any of the following anti-cancer therapies prior to imaging agent administration within the stated timeframes:
- •Prior treatment with any therapeutic radiopharmaceutical
- •< 10 half-lives for any imaging radiopharmaceutical
- •=< 4 weeks for external beam radiation therapy (EBRT) or brachytherapy
- •=< 6 months for lung-directed external beam radiotherapy
- •Patients with non-tumore uptake of [68Ga]Ga-DWJ155 in tissues or organs that, in the opinion of the investigator, increases the risk associated with [177Lu]Lu-DWJ155 treatment.
研究者
相似试验
招募中
1 期
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors2025-521702-18-00Novartis Pharma AG27
尚未招募
不适用
BG-C137-101Advanced Solid TumorjRCT203125059119
招募中
不适用
A Phase 1 Study of MK-4884 for Advanced/Metastatic Solid Tumorsadvanced/metastatic solid tumorsadvanced/metastatic solid tumors (CRC, RCC, NSCLC, BTC)jRCT20312601236
招募中
1 期
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.2023-510356-23-00Novartis Pharma AG76
招募中
1 期
A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of CND261 in Patients with Seropositive Rheumatoid Arthritis2025-523265-15-00Candid Therapeutics Inc.9